Biomarkers predicting treatment outcome in depression: what is clinically significant?

Area of Science:

• Psychiatric pharmacogenomics
• Biomarker discovery
• Clinical trial design

Background:

• The Hamilton Rating Scale for Depression (HRSD) is a standard measure in depression clinical trials.
• A three-point difference in HRSD is a consensus criterion for clinical significance in treatment studies.
• Extending this criterion to biomarker studies is crucial for interpreting genetic and other biological markers.

Purpose of the Study:

• To establish a framework for assessing the clinical significance of biomarkers in depression treatment.
• To translate the established three-point HRSD difference criterion to biomarker effect sizes.
• To provide guidance for evaluating the predictive value of biomarkers in depression.

Main Methods:

• Simulated datasets modeled on large-scale clinical trials were used for analysis.
• Calculations determined the HRSD point differences required for biomarkers to explain similar variance as a three-point HRSD difference.
• Effect sizes for continuous biomarkers and number needed to assess were computed.

Main Results:

• A three-point HRSD difference explains 6.3% of outcome variance in typical trials.
• Biomarkers require specific per allele HRSD differences (e.g., 2.2–4.7 points) based on minor allele frequency to achieve similar explanatory power.
• A continuous biomarker needs an effect size of 1.5 HRSD points per standard deviation, with a number needed to assess of three.

Conclusions:

• This study provides quantitative guidance for assessing the clinical significance of biomarkers in depression.
• The findings enable researchers to interpret biomarker effects in the context of established clinical significance criteria.
• This work supports the development and validation of predictive biomarkers for depression treatment.